Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov:30 Suppl 2:1-2.
doi: 10.1111/ene.15996.

The 20th anniversary of the first clinical use of Stalevo®

Peter Jenner, Werner Poewe, Heinz Reichmann
Editorial

The 20th anniversary of the first clinical use of Stalevo®

Peter Jenner et al. Eur J Neurol. 2023 Nov.
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):939-953. doi:10.1016/S1474-4422(18)30295-3
    1. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021;397(10291):2284-2303. doi:10.1016/S0140-6736(21)00218-X
    1. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110:517-536. doi:10.1007/s00702-002-0808-2
    1. Wüllner U, Borghammer P, Choe CU, et al. The heterogeneity of Parkinson's disease. J Neural Transm. 2023;130:827-838. doi:10.1007/s00702-023-02635-4
    1. Peña-Díaz S, García-Pardo J, Ventura S. Development of small molecules targeting α-synuclein aggregation: a promising strategy to treat Parkinson's disease. Pharmaceutics. 2023;15:839. doi:10.3390/pharmaceutics15030839

Publication types

LinkOut - more resources